Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06989359 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease
A Phase 2 study of IgAN and C3G, sponsored by ADARx Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
- 12
- Study locations
NCT06989359 is a Phase 2 study of IgAN and C3G that is actively recruiting participants, run by ADARx Pharmaceuticals. The registered enrollment target is 45 participants, below the 245-participant average among 3 other IgAN trials with a reported enrollment target (82% lower). The trial reports 12 study locations across 6 states.
The verdict
NCT06989359, a Phase 2 study of IgAN and C3G, is actively recruiting participants, sponsored by ADARx Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
- 12
- Study locations
Study Summary
This Phase 2 study is designed to assess the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of ADX-038 in adults with complement-mediated kidney diseases.
Conditions Studied
Interventions
- DRUG ADX-038 Dose Level 2
- DRUG ADX-038 Dose Level 1
Study Locations (12)
Other
- ADARx Clinical Site - Pok Fu Lam
- ADARx Clinical Site - Shatin
- ADARx Clinical Site - Cheonan
- ADARx Clinical Site - Seoul
New South Wales
- ADARx Clinical Site - Wollongong
- ADARx Clinical Site - Gyeonggi-do
- ADARx Clinical Site - Seoul
Texas
- ADARx Clinical Site - Dallas
- ADARx Clinical Site - Houston
Louisiana
- ADARx Clinical Site - Shreveport
Michigan
- ADARx Clinical Site - Shelby
South Dakota
- ADARx Clinical Site - Dakota Dunes
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2025-08-28 |
| Est. Completion | 2028-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06989359
The ClinicalTrials.gov registry entry for NCT06989359 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 245-participant average among 3 other IgAN trials with a reported enrollment target (82% lower). The listed sponsor is ADARx Pharmaceuticals, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with IgAN appearing as the primary indexed condition, and to 2 interventions - of which ADX-038 Dose Level 2 is the first listed.
NCT06989359 reports 12 study locations spanning 6 distinct geographic areas - top geographies include Other, New South Wales, Texas.
Frequently Asked Questions
What is clinical trial NCT06989359 about?
NCT06989359 is a clinical study titled "Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease". This Phase 2 study is designed to assess the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of ADX-038 in adults with complement-mediated kidney diseases.
What is the current status of trial NCT06989359?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2025-08-28. Estimated completion is 2028-07.
What conditions does trial NCT06989359 study?
This clinical trial studies the following conditions: IgAN, C3G, IC-MPGN, IgA Nephropathy (IgAN), Complement-mediated Kidney Disease.
What interventions are being tested in trial NCT06989359?
The interventions under investigation include: ADX-038 Dose Level 2 (DRUG), ADX-038 Dose Level 1 (DRUG).
Who is sponsoring clinical trial NCT06989359?
This trial is sponsored by ADARx Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06989359 being conducted?
This trial has 12 study locations across Louisiana, Michigan, South Dakota, Texas, New South Wales. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for IgAN
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.